United Therapeutics (UTHR) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

United Therapeutics (UTHR) overview

United Therapeutics (UTHR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3,183m and operating profit of USD 1,493m; the year-end share price was 487.25 USD and market capitalisation was USD 21,265m. United Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get United Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 7,096mFY 2025
Share price487.25 USDFY 2025 year end
RevenueUSD 3,183mFY 2025
Operating profitUSD 1,493mFY 2025
Net earningsUSD 1,335mFY 2025
Market capitalisationUSD 21,265mFY 2025 year end

About United Therapeutics

United Therapeutics develops and sells pharmaceutical therapies for people with serious diseases, particularly pulmonary arterial hypertension and related pulmonary conditions. Its marketed products include inhaled treprostinil, injectable and oral therapies, delivery pumps, and tadalafil tablets; it also sells a treatment for high-risk neuroblastoma. The company additionally develops technologies intended to expand the availability of transplantable organs.

Generate the United Therapeutics report

United Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for United Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on United Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.